Authors:
Shulman, NS
Machekano, RA
Shafer, RW
Winters, MA
Zolopa, AR
Liou, SH
Hughes, M
Katzenstein, DA
Citation: Ns. Shulman et al., Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy, J ACQ IMM D, 27(4), 2001, pp. 377-380
Authors:
Shulman, N
Zolopa, AR
Passaro, D
Shafer, RW
Huang, W
Katzenstein, D
Israelski, DM
Hellmann, N
Petropoulos, C
Whitcomb, J
Citation: N. Shulman et al., Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy, AIDS, 15(9), 2001, pp. 1125-1132
Authors:
Shafer, RW
Hertogs, K
Zolopa, AR
Warford, A
Bloor, S
Betts, BJ
Merigan, TC
Harrigan, R
Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
Authors:
Shulman, NS
Zolopa, AR
Passaro, DJ
Murlidharan, U
Israelski, DM
Brosgart, CL
Miller, MD
Van Doren, S
Shafer, RW
Katzenstein, DA
Citation: Ns. Shulman et al., Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response, J ACQ IMM D, 23(3), 2000, pp. 221-226
Authors:
Bangsberg, DR
Hecht, FM
Charlebois, ED
Zolopa, AR
Holodniy, M
Sheiner, L
Bamberger, JD
Chesney, MA
Moss, A
Citation: Dr. Bangsberg et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population, AIDS, 14(4), 2000, pp. 357-366
Authors:
Zolopa, AR
Shafer, RW
Warford, A
Montoya, JG
Hsu, P
Katzenstein, D
Merigan, TC
Efron, B
Citation: Ar. Zolopa et al., HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed, ANN INT MED, 131(11), 1999, pp. 813